AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

RecruitingPhase 2Ages 18 Years - 90 YearsAllThe University of Texas Health Science Center, Ho…
💬

In plain words

What the trial is, and whether it could suit you

The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be detected the urine, and major adverse kidney events (MAKE) at day 30 postoperatively, compared to famotidine after cardiac surgery. The specific aims of the study will be achieved by randomizing a group of 400 patients to receive pantoprazole (study) or famotidine (control) for 3 days perioperatively. Our study population will include any adult patients (aged over 18 years) scheduled for cardiac su

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (age 18-90). * Scheduled for elective cardiac surgery with cardiopulmonary bypass. * Moderate to high risk of developing AKI (Cleveland risk score equal to or higher than 3. Exclusion Criteria: * Patients with preoperative eGFR\<30 ml/min/1.73 m2 * Dialysis dependence * Emergency surgery * Pregnancy. * Nursing patient * Patients with interstitial nephritis * PPIs hypersensitivity * Liver disease * Vitamin B12 deficiency.
💊

What it tests

  • Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days
  • Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
📍

Where

1 site
Memorial Hermann Texas Medical Center
Houston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy